# Medgencell.com

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medgencell-com

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.medgencell.com
- Latest round: Angel (Aug 26, 2015)
- Investors on record: 3

## About

Established in 2015 and based in Chengdu, China, Medgencell.com operates as a biotechnology company dedicated to providing cell therapy technology research and development services. It has acquired Chengdu Top Innovation and Entrepreneurship Team Certificate. In January 2025, Medgencell.com closed a strategic investment from new investor Zhongguancun Development Venture.

The company mainly provides precision cell therapy technology research and development and services. Its self-developed CRISPR gene-edited T-cell product has undergone Phase I clinical trials at West China Hospital of Sichuan University. Medgencell.com also possess technologies such as tumour cell biotherapy technology and stem cell regenerative medicine industrialization. The services can be used in breast cancer, lung cancer, anti-ageing, disease rehabilitation and other fields. It also provides four major technology platforms which are genome editing and epigenetic modification, in vitro rapid amplification, in vitro rapid evaluation of cell drugs, and non-viral transfection.

The company generates revenue by providing cell therapy technology research and development services. 

The company will use the funds to develop cell-based therapies.

## Funding rounds

- Angel, Aug 26, 2015 — Ping An Trust, Sichuan Development Industry Led Equity Investment Fund Management, Sichuan Venture Capital

## Investors

- Ping An Trust — Angel
- Sichuan Development Industry Led Equity Investment Fund Management — Angel
- Sichuan Venture Capital (https://capitalatlas.ai/funds/sichuan-venture-capital) — Angel